Deferoxamine mesylate

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

138-14-7

包装与价格：

包装	价格(元)
100mg	电议
500mg	电议

产品介绍

化学性质

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	656.79
Cas No.	138-14-7
Formula	C₂₆H₅₂N₆O₁₁S
Solubility	≥65.7 mg/mL in H2O; insoluble in EtOH; ≥29.8 mg/mL in DMSO
Chemical Name	(Z)-4-((5-aminopentyl)(hydroxy)amino)-N-(5-((Z)-N,4-dihydroxy-4-((5-(N-hydroxyacetamido)pentyl)imino)butanamido)pentyl)-4-oxobutanimidic acid compound with methanesulfonic acid (1:1)
Canonical SMILES	CC(N(O)CCCCC/N=C(O)/CCC(N(O)CCCCC/N=C(O)/CCC(N(O)CCCCCN)=O)=O)=O.CS(O)(=O)=O
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Deferoxamine mesylate是一种特异性的铁螯合剂[1][2][3]。

Deferoxamine mesylate可用于治疗急性铁中毒。Deferoxamine与铁复合形成ferrioxamine，从而阻止铁进入进一步的化学反应。形成的螯合物易溶于水，可通过肾脏排出[1]。

在移植13762NF乳腺癌的Fisher大鼠中，deferoxamine mesylate减少大鼠肿瘤生长。而deferoxamine mesylate注射加上低铁饮食对肿瘤生长具有最大的抑制效应。Deferoxamine mesylate可能是治疗乳腺癌的有用的化疗剂[2]。在Sprague-Dawley大鼠中，deferoxamine mesylate (75-90 mg; 300 mg/kg)在手术前通过腹腔动脉给药。Deferoxamine mesylate可以显著降低原位肝移植后淀粉酶、脂肪酶和丙二醛（MDA）的血清水平。Deferoxamine mesylate也可以通过上调HIF-1的表达和抑制氧化毒性反应，从而保护胰腺组织[3]。

参考文献：
Deferoxamine mesylate (Desferal mesylate). A specific iron-chelating agent for treating acute iron intoxication. Clin Pharmacol Ther. 1969 Jul-Aug;10(4):595-6.
Wang F, Elliott RL, Head JF. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res. 1999 Jan-Feb;19(1A):445-50.
Li Y, Zhang PJ, Jin C, et al. Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats. Transplant Proc. 2011 Jun;43(5):1450-5.

试验操作

Cell experiment:[1]
Cell lines	Adipose derived mesenchymal stem cells (AdMSCs)
Reaction Conditions	30, 60 or 120 μM deferoxamine mesylate for 12 h inubation
Applications	Cells exposed to 30 or 60 μM of deferoxamine mesylate showed significantly lower expression of hypoxia-inducible factor-1α (HIF-1α) when compared with cells cultured under 1% O₂, but cell treated with 120 μM deferoxamine mesylate was able to mimic cells under hypoxic conditions. Deferoxamine mesylate could promote wound healing in AdMSCs through HIF-1α stabilization.
Animal experiment:[2]
Animal models	Sprague-Dawley rats, 0.25 ~ 0.30 kg
Dosage form	75 ~ 90 mg; 300 mg/kg Injected via the celiac artery at 24 and 48 hours before orthotopic liver autotransplantation
Applications	Deferoxamine mesylate significantly lowered the serum levels of amylase, lipase, and malondialdehyde after orthotopic liver autotransplantation. Deferoxamine mesylate also protected pancreatic tissue through up-regulated expression of HIF-1α protein and inhibition of oxidative toxic reactions.
Note	The technical data provided above is for reference only.
	References: 1. Wahl EA, Schenck TL, Machens HG, et al. VEGF released by deferoxamine preconditioned mesenchymal stem cells seeded on collagen-GAG substrates enhances neovascularization. Scientific Reports, 2016, 6: 36879. 2. Li Y, Zhang PJ, Jin C, et al. Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats. Transplantation Proceedings, 2011, 43(5): 1450-1455.